CDC recommends new dosing schedule for Trumenba vaccine | Courtesy of Shutterstock
+ Technology/Innovation
Amanda Rupp | Nov 2, 2016

CDC recommends new dosing schedule for Trumenba vaccine

The Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC) recently released new recommendations for the dosing schedule of Trumenba (Meningococcal Group B) vaccinations.

This new recommendation offers updated outlines for administering the two or three-dose series of vaccinations.

According to dosing guidelines, people who have an increased chance of meningococcal disease, or serogroup B outbreaks, should receive their three Trumenba doses at one to two months as well as six months.

Healthy adolescents who do not qualify for an increased risk should receive their two Trumenba doses at zero and six months. If they receive their second dose at less than six months, they should receive their third dose at a minimum of six months after receiving the first dose.

“Today’s ACIP recommendation is an important update that offers clear guidance to health care providers administering Trumenba to help prevent meningococcal group B disease, also known as MenB, in healthy adolescents and young adults, as well as those at increased risk for the disease,” Dr. Laura York, global medical lead for meningococcal vaccines at Pfizer Vaccines, said. “This new recommendation enables flexible vaccination dosing intervals depending on one’s risk of exposure to MenB, which makes it easier for health care providers to help protect individuals from this uncommon but life-threatening disease.”

Organizations in this story

+ Pfizer

More News